Today, "early detection, early diagnosis, early treatment" is still the most effective means for humans to fight cancer. As the cost of gene sequencing continues to decline, more and more researchers and startups are investing in the development and application of ctDNA detection technology. For example, the previously reported startups U-Tech, Ankeji, and Mainega , pan-sub, etc. The ctDNA test is expected to be more efficient and convenient for early detection and diagnosis of cancer. The development of this technology is attracting continued attention in the capital market. Established in March 2016, Shenzhen Yinhe Biotechnology Co., Ltd. is committed to popularizing early tumor screening technology in asymptomatic populations. It is hoped that ctDNA technology will be used to detect very early cancerous changes, so as to eliminate or control it in time. The early screening principle of cancer based on ctDNA detection technology is not complicated, but it faces three challenges. Dr. Liu Chaojun, head of the research and development department of Hebi, said in an interview that the sensitivity and accuracy of ctDNA detection technology, the baseline based on large sample database, and the intervention after early detection are three problems that need to be solved for early cancer screening. In fact, the goal of increasing sensitivity and accuracy has already placed a fairly high demand on startups. Because ctDNA is very low in peripheral blood, it is usually only a few thousandths, and for very early precancerous lesions, the ctDNA content may be as low as one in ten thousand. Therefore, to accurately detect, the technical requirements are very high. In addition, detection techniques also need to consider the issue of background noise. For example, NGS high-throughput sequencing itself has an error of one thousandth, so the impact of this error on ctDNA detection results must be eliminated. In terms of detection sensitivity and accuracy, the breakthrough of Hebi Bio is mainly because the TNR-ctDNA technology developed by the company can eliminate the noise existing in the ctDNA detection process. "TNR-ctDNA has achieved triple noise reduction in sample preparation, sequencing, genetic information, etc., effectively improving the sensitivity and accuracy of detection technology." Liu Chaoyu said that the sensitivity of TNR-ctDNA has reached 10,000. Third, "We are working hard to make the sensitivity reach one in ten thousand." Roxadustat Intermediate Roxadustat Intermediate,Fg-4592 Intermediate,Cas 1455091-10-7,Cas 1455091-10-7 Roxadustat Intermediate Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com